PURE Bioscience Reports Fiscal Q2 2026 Results: Expanding Verticals, New Product Launch, and Continued Revenue Growth

Key Highlights from Fiscal Q2 2026 Results

• Net Product Sales Growth: PURE Bioscience, Inc. (OTCQB: PURE) reported net product sales of \$443,000 for the fiscal second quarter ended January 31, 2026, representing a year-over-year increase of \$52,000 compared to \$391,000 in Q2 2025. For the six months ended January 31, 2026, net product sales were \$1,150,000, up \$204,000 from the prior year’s \$946,000.
• Reduced Net Loss: The net loss for Q2 2026 was \$785,000, an improvement from \$798,000 in the prior-year quarter. For the six-month period, the net loss narrowed to \$1,249,000 from \$1,487,000 in the comparable period last year. Excluding share-based compensation, the net loss for the quarter was \$727,000, down from \$771,000, and for the six months was \$1,157,000, down from \$1,403,000.
• Operational Efficiency: Selling, general, and administrative expenses decreased by \$24,000 in the quarter and \$162,000 for the six-month period, attributed to reductions in board fees and personnel costs. These savings were partially offset by increased interest expenses related to the company’s notes payable balance.
• Stable Loss Per Share: Net loss per share remained steady at (\$0.01) for both the quarter and six-month periods in 2026 and 2025.

Strategic and Business Developments

• USDA Biobased Product Certification: PURE received the highly anticipated USDA Biobased Product Certification for its new product, PURE Clean. The company expects to officially launch PURE Clean and fulfill pre-orders during the fiscal third quarter. This certification could be a significant growth catalyst as it opens up new market opportunities, especially in sectors prioritizing sustainability.
• New Product Launch: The upcoming release of PURE Clean, following its USDA BioPreferred Program certification, positions PURE to capitalize on the growing demand for biobased, non-toxic antimicrobial solutions.
• Expansion in Dairy Sector: The company is validating and rolling out new in-plant dairy applications, including ongoing testing and trials at Cal Poly San Luis Obispo. A dedicated marketing campaign now directly targets dairy farmers, emphasizing new membrane and pasteurizer treatments.
• Biomedical Market Entry: PURE has initiated exploration of the biomedical sector in partnership with Quip Laboratories, seeking to establish a presence in this new vertical.
• Broader Market Access: Distribution partner Bonsai is leveraging its online platform to drive promotion and sales of PURE products in the B2B janitorial and sanitation markets, while also increasing consumer access.
• Growth in Transportation Sector: The company reports continued sales growth in the transportation industry, supported by the development of new equipment designed specifically for trailer treatments.

Management Perspective

Tim Steffensmeier, Vice President of Sales, noted, “The Company is advancing with disciplined execution. We are converting in-plant validations into recurring commercial programs, deepening our presence within the food and beverage vertical, and preparing to launch PURE Clean following its USDA BioPreferred® Program certification. At the same time, we are strategically expanding into the food transportation sector and the biomedical space through focused partnerships, while positioning PURE solutions for broader market accessibility. Our priority is clear – accelerate adoption, diversify with intention, and expand market reach to drive sustained revenue growth.”

Financial Position and Balance Sheet Considerations

• Liquidity: As of January 31, 2026, PURE held cash and cash equivalents of \$198,000, down from \$334,000 at July 31, 2025. Restricted cash remained stable at \$75,000.
• Working Capital: Accounts receivable decreased to \$252,000 from \$474,000, and inventories increased to \$244,000 from \$141,000, reflecting potentially higher production activity in anticipation of new product launches.
• Liabilities: Current liabilities jumped significantly to \$3,055,000 (from \$938,000), driven by the reclassification of \$2,139,000 in convertible notes payable to related parties from non-current to current status. Total liabilities rose to \$7,061,000 (from \$6,174,000), while total stockholders’ deficiency widened to \$6,273,000 (from \$5,116,000).
• Share Count: The company had 111,886,473 shares of common stock outstanding as of January 31, 2026.

Potentially Price-Sensitive Issues for Shareholders

• Product Launches and New Certifications: The USDA certification and upcoming launch of PURE Clean could significantly impact sales and market perception, potentially driving share price appreciation if adoption accelerates.
• Expansion into New Verticals: Entry into the biomedical sector and continued momentum in transportation and dairy could diversify revenue streams and reduce business risk.
• Rising Current Liabilities: The reclassification of convertible notes payable to current liabilities indicates upcoming debt maturities or refinancing needs, which could pressure liquidity and may necessitate new financing or dilution.
• Continued Net Losses and Cash Burn: While losses have narrowed, the company continues to operate at a loss with decreasing cash reserves. The ability to achieve profitability and secure additional funding will be crucial for long-term sustainability and could be a key driver of share price movement.

About PURE Bioscience

PURE Bioscience specializes in patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial solutions, focusing on high safety and efficacy for the food, beverage, and increasingly biomedical and transportation industries. The company’s SDC-based technology aims to offer superior efficacy, lower toxicity, and mitigate bacterial resistance compared to traditional chemical treatments.

Forward-Looking Risks

Investors should note that PURE’s future performance remains subject to several risks, including but not limited to: failure to achieve anticipated benefits from business initiatives; acceptance and adoption of new products; ability to maintain partnerships; sufficiency of revenues and cost reductions to achieve profitability; need for additional funding; regulatory approval timelines; and competitive dynamics that could impact SDC product adoption versus cheaper alternatives.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions.

View PURE BIOSCIENCE, INC. Historical chart here